Company Overview of BioMarck Pharmaceuticals, Ltd.
BioMarck Pharmaceuticals, Ltd., a biopharmaceutical company, discovers and develops drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. The company develops BIO-11006 Inhalation Solution that inhibits the function of the myristoylated alaninerich C kinase substrate, which is a vital component for secretion of mucus and inflammatory mediators. Its product also targets chronic obstructive pulmonary disease, as well as other diseases, such as asthma and cystic fibrosis. BioMarck Pharmaceuticals, Ltd. was founded in 2002 and is based in Durham, North Carolina.
Westpark Corporate Center
4364 South Alston Avenue
Durham, NC 27713-2280
Founded in 2002
Key Executives for BioMarck Pharmaceuticals, Ltd.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
|3D Biomatrix Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact BioMarck Pharmaceuticals, Ltd., please visit www.biomarck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.